The efficacy of LAB-produced bacteriocins was evaluated for use in regulating oral biofilms (Zoumpopoulou et al. 2013). It is important to note that bacteriocin, bacteriocinogenic strains require generally recognized as safe (GRAS) status in order to be sold on the US market. In other hand, Tong and co-workers also studied exclusively for therapeutics treatment against oral biofilms, lantibiotic nisin, in combination with free amino acids against Steptococcus mutans biofilms. This result indicated mixtures of either the L or D-enantiomers of Glu, Asp or Cys in combination with nisin had been providing the impact of the lantibiotic against biofilms of S. mutans (Tong et al. 2014a). Another interesting study (Lobos et al. 2009) treated against oral pathogens, the combination of the bacteriocin PsVP-10, a non-lantibiotic (class II bacteriocins), with the antimicrobials substances (triclosan and chlorhexidine). In results showed better synergistics effect against S. mutans and S. sobrinus. A recent research exhibited that nisin interacts synergistically with chloramphenicol were effectively against Staphylococcus pseudintermedius DSM21284 biofilms, though combinations of nisin I4V with penicillin were mainly potent against DSM21284 planktonic cells (Field et al. 2016a). In additional emerged study, nisin synergy with ciprofloxacin or daptomycin was effectively treated against methicillin-resistant S. aureus (MRSA) biofilms (Dosler and Mataraci 2013). Indeed, bacteriocins seem to be advanced candidates for the treatment of MRSA biofilms, since they both enhance anti-biofilm activities and preventing the emergence of resistance when used either alone or in combination with antibiotics. Tong et al., (2014a) also reported the efficacy of nisin in synergy with chloramphenicol, ciprofloxacin or penicillin at controlling biofilms of the nosocomial pathogen, E. faecalis (Tong et al. 2014b).